Literature DB >> 10739975

[Thalidomide and thrombosis].

B Flageul1, D Wallach, B Cavelier-Balloy, H Bachelez, F Carsuzaa, L Dubertret.   

Abstract

BACKGROUND: Teratogenicity and neuropathy are the well known serious side effects induced by thalidomide. We describe 5 cases of thrombotic events occurring within a brief delay after the onset of thalidomide in a manner that suggests that thalidomide could have acted as a precipiting or as a starting factor in these events. OBSERVATIONS: Five patients including 4 patients with lupus erythematosus (1 discoid lupus, 1 subacute lupus and 2 systemic lupus erythematosus) and one patient with a severe atopic dermatitis, all without previous history of vascular events, developed an arterial thrombosis (2 cases) or a venous thrombosis (3 cases), severe in 4 cases, few days or weeks after the onset of thalidomide treatment (50 to 100 mg daily). DISCUSSION: All the patients had risk factors of thrombosis: the presence of antiphospholipids and/or anticardiolipin antibodies in lupus erythematosus patients and a trauma in the atopic case. However the absence of a previous story of thrombosis, its rapid occurrence after the onset of thalidomide and its severity are intriguing. In addition, recent studies demonstrate that thalidomide has various effects that would act, among other things, on angiogenesis. Thus, we think that a doubt exists on a negative effect of thalidomide in thrombosis risk factors patients and that this hypothesis has to be confirmed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739975

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  1 in total

1.  Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme.

Authors:  Fabian Baumann; Miroslava Bjeljac; Spyros S Kollias; Brigitta G Baumert; Sebastian Brandner; Valentin Rousson; Yasuhiro Yonekawa; René L Bernays
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.